Intensive Lipid Therapy Lowers Plaque Lipid Content

Carotid plaque lipid content decreases significantly after one year of therapy, lasts in second year

THURSDAY, Oct. 20 (HealthDay News) -- Significant decreases are observed in carotid plaque lipids after one year of intensive lipid therapy and continue in the second year, according to a study published in the Sept. 1 issue of the Journal of the American College of Cardiology: Cardiovascular Imaging.

Xue-Qiao Zhao, M.D., from the University of Washington in Seattle, and colleagues investigated whether intensive lipid therapy affected plaque lipid content, and used high-resolution magnetic resonance imaging (MRI) to establish the change in carotid plaque morphology and composition during lipid therapy. A total of 33 patients with measureable lipid-rich necrotic core (LRNC) at baseline, coronary or carotid artery disease, apolipoprotein B ≥120 mg/dL, and lipid treatment history of less than one-year were randomized to receive atorvastatin monotherapy or atorvastatin-based combination therapies with appropriate placebos for three-years. Quantification of wall area and plaque composition was analyzed using MRI images.

The investigators identified a significant reduction in plaque lipid content after three years of therapy for all patients, with average LRNC volume decreasing from 60.4 to 37.4 mm³ and average percent LRNC (LRNC area/wall area in lipid-rich regions) decreasing from 14.2 to 7.4 percent. The decreases in percent LRNC in the first, second, and third years were 3.2 (P < 0.001), 3.0 (P = 0.005), and 0.91 percent (P = 0.2), respectively, with a similar LRNC volume pattern of changes. There was a significant decrease in the average percent wall volume in lipid-rich regions from 52.3 to 48.6 percent, which was significantly higher in slices containing LRNC than those without.

"These findings suggest a potential mechanism for plaque stabilization associated with intensive lipid therapy," the authors write.

The study was partially funded by Pfizer; the study medications were provided by Pfizer, Abbott Laboratories, and Daiichi Sankyo.

Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events